Table 4.

Effect of ARR on biochemical failure-free survival. Results from Cox models (a) unadjusted and (b) adjusted for clinical characteristics.

BFS		(a) Unadjusted Model		(b) Adjusted Model
Variable	Years since RT	Hazard Ratio	95% CI	Hazard Ratio	95% CI	p-value
ARR < 1.1 vs. ARR > 1.1	0	5.8	(2.0, 16)	3.4	(1.10, 10.34)
	1	3.2	(1.7, 5.9)	1.7	(0.84, 3.27)
	2	2.3	(1.5, 3.5)	1.1	(0.67, 1.79)
	3	1.8	(1.2, 2.6)	0.81	(0.52, 1.27)
	4	1.5	(0.98, 2.2)	0.65	(0.40, 1.04)
ln(bPSA + 1)+				2.11	(1.6, 2.7)	<.0001
Gleason*: GS 7 vs. GS 2–6				1.69	(1.1, 2.5)	0.01
Gleason: GS 8-10 vs. GS 2–6				1.92	(1.1, 3.4)	0.03
T-stage**: T2 vs. T1				1.42	(0.82, 2.5)	0.21
T-stage: T3/T4 vs. T1				1.69	(0.84, 3.4)	0.14
Total Dose+				0.97	(0.94, 1.0)	0.04
Age at RT+				0.99	(0.96, 1.02)	0.41
Whole Pelvis				1.4	(0.90, 2.3)	0.13
White vs. Non-White				0.68	(0.42, 1.08)	0.10

Abbreviations: ARR = Adjusted Ratio of Rise; bPSA = pretreatment PSA; RT = radiation therapy. Model stratified by hospital.

⁺Hazard ratios for a 1-unit increase.

^*p-value for overall Gleason Score effect = 0.02.

^**p-value for overall T-stage effect = 0.31